Lexington, Mass.-based Concert Pharmaceuticals named Dr. James Shipley to the newly created role of chief medical officer.
Concert Pharmaceuticals names first CMO
Shipley, 58, is charged with overseeing the company's clinical research, operations and pharmacology, as well as regulatory affairs and quality assurance. He previously was senior vice president of clinical development, medical and regulatory affairs for Lexington-based Indevus Pharmaceuticals, which was bought by Endo Pharmaceuticals, Newark, Del., in 2009. Before that, he was senior vice president of clinical research at Praecis Pharmaceuticals, Waltham, Mass., bought by GlaxoSmithKline in 2007.
Send us a letter
Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.